Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
Host: William J. Gradishar, MD
\n\n Guest: Javier Cortes, MD, PhD
\n\n Guest: Hope S. Rugo, MD, FASCO
\n\n\n \n
Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.